Masaharu Nomura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Masaharu Nomura has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- György Marko-Varga
Clinical Protein Science & Imaging, Department of Biomedical Engineering, Lund University, 22242 Lund, Sweden
1 shared publication - Harubumi Kato
Department of Thoracic Surgery, Niza Shiki Central General Hospital
1 shared publication - Hiromasa Tojo
Dept. of Biophysics and Biochemistry Osaka University Graduate School of Medicine 2‐2 Yamadaoka 565‐0871 Suita Japan
1 shared publication - Junichiro Fujimoto
Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan
1 shared publication - Norihiko Ikeda
Department of Surgery Tokyo Medical University Tokyo Japan
1 shared publication - Roland Andersson
Skåne University Hospital
1 shared publication
Latest Publications
- Open Access
- 22 November 2014
- Published by Wiley in Clinical and Translational Medicine
- Vol. 3 (1) , 61
Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories
The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers.Data from joint lung cancer studies are presented where protein expression from Neuro‐ Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell‐ (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre‐therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.
- 22 November 2014
- Published by Wiley in Clinical and Translational Medicine
- Vol. 3 (1) , 61
Open AccessClinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories
The Tokyo Medical University Hospital in Japan and the Lund University hospital in Sweden have recently initiated a research program with the objective to impact on patient treatment by clinical disease stage characterization (phenotyping), utilizing proteomics sequencing platforms. By sharing clinical experiences, patient treatment principles, and biobank strategies, our respective clinical teams in Japan and Sweden will aid in the development of predictive and drug related protein biomarkers.Data from joint lung cancer studies are presented where protein expression from Neuro‐ Endocrine lung cancer (LCNEC) phenotype patients can be separated from Small cell‐ (SCLC) and Large Cell lung cancer (LCC) patients by deep sequencing and spectral counting analysis. LCNEC, a subtype of large cell carcinoma (LCC), is characterized by neuroendocrine differentiation that small cell lung carcinoma (SCLC) shares. Pre‐therapeutic histological distinction between LCNEC and SCLC has so far been problematic, leading to adverse clinical outcome. An establishment of protein targets characteristic of LCNEC is quite helpful for decision of optimal therapeutic strategy by diagnosing individual patients. Proteoform annotation and clinical biobanking is part of the HUPO initiative (http://www.hupo.org) within chromosome 10 and chromosome 19 consortia.